ArticleCellular and molecular neurobiology2025
Elevated Plasma m6A Demethylase FTO Levels Predict Favorable Outcomes Following Acute Ischemic Stroke.
Article in Cellular and molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Role and Diagnostic Efficacy of the METTL14/GADD45B mCellular and molecular neurobiology · 2026Article
- The role of N6-methyladenosine associated genes in ischemic stroke risk: interplay with environmental factors.Journal of thrombosis and thrombolysis · 2026Review
- The Clinical Relevance of FTO as a Demethylase Beyond Cancer: Molecular Mechanisms and Therapeutic Opportunities.Aging and disease · 2025Review
- Comprehensive analysis of m6A RNA methylation regulators and the immune microenvironment in spinal cord injury.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
N6-methyladenosine (m6A) modification is prevalent in the mammalian brain and functions as a significant epigenetic regulator in neurological disorders, including ischemic stroke. The fat mass and obesity-associated protein (FTO) was the first m6A demethylase to be identified. The objective of this study was to assess the prognostic significance of FTO in patients with acute ischemic stroke (AIS). A cohort consisting of 201 AIS patients and 53 healthy controls were enrolled, and their plasma FTO concentrations were measured. The findings demonstrated that FTO levels were remarkably lower in AIS patients compared to healthy controls (254.80 [229.89, 274.77] vs. 395.67 [271.34, 544.17], p < 0.001), and they were significantly diminished in patients with unfavorable outcomes compared to those with favorable outcomes (250.73 [208.34, 290.77] vs. 257.03 [236.47, 283.96], p = 0.016). Additionally, FTO concentration exhibited a negative correlation with 3-month modified Rankin scale (mRS) scores in ischemic stroke patients (r = - 0.1635, p = 0.0204). Univariate and multivariate logistic regression analyses revealed that plasma FTO levels were associated with the functional outcomes at 3 months. After adjusting for potential confounding variables, elevated FTO levels independently predicted the 3-month favorable outcomes (odds ratio [OR] = 0.986 (0.977-0.996), p = 0.004). Besides, the inclusion of FTO in the clinical model notably enhanced the discrimination and risk reclassification (integrated discrimination improvement = 5.34% (2.37-8.31%), p = 0.0004); continuous net reclassification improvement = 44.07% (17.33-70.82%), p = 0.0012). A nomogram incorporating FTO showed good calibration, discrimination, and clinical utility. Consequently, our study demonstrated that admission plasma FTO levels are independently linked to the 3-month outcomes for patients with AIS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.